Kemin Industries Acquires Archangel Inc.

Kemin Industries Acquires CJ Youtell Biotech

September 23, 2025

Biotechnology

Kemin Industries has acquired CJ Youtell Biotech, the enzymes and fermentation subsidiary of CJ Bio, gaining full ownership of CJ Youtell’s fermentation plants and enzyme product portfolio. The acquisition adds fermentation capacity in Shandong and Hunan, China and expands Kemin’s global enzyme R&D, manufacturing and product offerings across animal feed, food, aquaculture and industrial end markets.

Kemin Industries Acquires Bio-Cide International

May 6, 2021

Food & Beverage

Kemin Industries has acquired Norman, Oklahoma–based Bio-Cide International, a specialist in chlorine dioxide–based antimicrobial technologies. The deal adds Bio-Cide's OXINE, PRO-OXINE, KEEPER and PURITE technologies to Kemin's portfolio to strengthen its food safety, animal nutrition/health and human health offerings.

Arcline Investment Management Acquires Majority Interest in Akron Biotechnology

September 11, 2019

Biotechnology

Arcline Investment Management has acquired a majority interest in Akron Biotechnology LLC, a supplier of cGMP-compliant materials and services for cell and gene therapy manufacturers. Akron will remain led by founder and CEO Dr. Claudia Zylberberg, and Arcline plans to expand Akron's manufacturing capacity and pursue complementary acquisitions to build a platform in regenerative medicine.

ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics

September 25, 2025

Biotechnology

ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.

Equillium Acquires Bioniz Therapeutics

February 16, 2022

Biotechnology

Equillium, Inc. (Nasdaq: EQ) acquired privately held Bioniz Therapeutics, obtaining exclusive worldwide rights to Bioniz's pipeline (BNZ-1, BNZ-2, BNZ-3) and proprietary discovery platform in an all-stock transaction (5,699,492 shares, ~19.3% of Equillium outstanding) plus up to $57.5M in development milestones and up to $250M in sales milestones. The acquisition expands Equillium's immunology capabilities and pipeline, adding complementary clinical-stage cytokine-targeting assets and key research and clinical personnel.

Rovensa Acquires Agro-K

December 5, 2023

Agriculture

Rovensa Group has acquired Agro-K, a family-owned U.S. biostimulants developer founded in 1976 and based in Minneapolis. Agro-K will be integrated into Rovensa Next to strengthen Rovensa's biosolutions portfolio and accelerate its expansion in the United States; financial terms were not disclosed.